Tumorâ€Associated Macrophages in the Progression of Hepatocellular Carcinoma
Abstract
Hepatocellular carcinoma (HCC) contains many immune cell matrices, which constitute the tumor microenvironment (TME). Tumor-associated macrophages (TAM) are the main compartments of immune cell matrix in HCC, which play an important role in the pathogenesis of HCC, including immunosuppression, angiogenesis, tumor invasion and metastasis, and malignant transformation of HCC stem cells. At present, targeted TAM therapy for HCC has achieved promising results by eliminating existing TAMs, blocking the recruitment of TAMs, reprogramming TAMs polarization, regulating TAMs products and restoring TAMs phagocytosis. This review summarizes our understanding of TAMs and HCC, and discusses the role of TAMs in the development of HCC.
References
[2] Foerster F, Gairing SJ, Ilyas SI, et al. Emerging immunotherapy for HCC: A guide for hepatologists [J]. Hepatology, 2022, 75(6): 1604-26.
[3] Cheng K, Cai N, Zhu J, et al. Tumor-associated macrophages in liver cancer: From mechanisms to therapy [J]. Cancer Commun (Lond), 2022, 42(11): 1112-40.
[4] Li Z, Wu T, Zheng B, et al. Individualized precision treatment: Targeting TAM in HCC [J]. Cancer Lett, 2019, 458(86-91.
[5] Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy [J]. Nat Rev Immunol, 2018, 18(9): 545-58.
[6] Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology [J]. Nat Rev Clin Oncol, 2017, 14(7): 399-416.
[7] Zhou B, Yang Y, Li C. SIRT1 inhibits hepatocellular carcinoma metastasis by promoting M1 macrophage polarization via NF-κB pathway [J]. Onco Targets Ther, 2019, 12(2519-29.
[8] Zong Z, Zou J, Mao R, et al. M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling [J]. Front Immunol, 2019, 10(1643.
[9] Zhu F, Li X, Chen S, et al. Tumor-associated macrophage or chemokine ligand CCL17 positively regulates the tumorigenesis of hepatocellular carcinoma [J]. Med Oncol, 2016, 33(2): 17.
[10] Sun D, Luo T, Dong P, et al. M2-polarized tumor-associated macrophages promote epithelial-mesenchymal transition via activation of the AKT3/PRAS40 signaling pathway in intrahepatic cholangiocarcinoma [J]. J Cell Biochem, 2020, 121(4): 2828-38.
[11] Bartneck M, Schrammen PL, Möckel D, et al. The CCR2(+) Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers [J]. Cell Mol Gastroenterol Hepatol, 2019, 7(2): 371-90.
[12] Zang M, Li Y, He H, et al. IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection [J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(12): 3759-70.
[13] Dalton HJ, Pradeep S, Mcguire M, et al. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression [J]. Clin Cancer Res, 2017, 23(22): 7034-46.
Copyright (c) 2023 Dingjie Liu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
